Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma

Peihua Lu • 16 Jun 2022
EHA 2022
Lymphoma CAR-T

In this video, Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, discusses the results of a study comparing the safety and efficacy of humanized versus murinized dual-targeting CD19/CD22 CAR-T cells for relapsed/refractory (R/R) lymphoma. While both products were well-tolerated, the overall response rate (ORR) was higher in patients receiving humanized CAR-T cells, and Dr Lu mentions the need for a longer follow-up of this study. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Peihua Lu

1:15
AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL
Peihua Lu • 9 Dec 2023
0:53
Anti-CD7 CAR-T therapy for T-ALL/LBL
Peihua Lu • 9 Dec 2023
3:16
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial
Peihua Lu • 9 Dec 2023
2:16
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals